Immunotherapeutics in Cancer Acid Serve as Novel Serum Biomarkers and Human Xeno-Autoantibodies against a Non-Human Sialic

Vered Padler-Karavani,Nancy Hurtado-Ziola,Minya Pu,Hai Yu,Shengshu Huang,Saddam Muthana,Harshal A. Chokhawala,Hongzhi Cao,Patrick Secrest,Dinorah Friedmann-Morvinski,Oded Singer,Darius Ghaderi,Inder M. Verma,Yu-Tsueng Liu,Karen Messer,Xi Chen,Ajit Varki,Richard Schwab
2011-01-01
Abstract:Human carcinomas can metabolically incorporate and present the dietary non-human sialic acid Neu5Gc, which differs from the human sialic acid N-acetylneuraminic acid (Neu5Ac) by 1 oxygen atom. Tumor-associated Neu5Gc can interact with low levels of circulating anti-Neu5Gc antibodies, thereby facilitating tumor progression via chronic inflammation in a human-like Neu5Gc-deficient mouse model. Here we show that human antiNeu5Gc antibodies can be affinity-purified in substantial amounts from clinically approved intravenous IgG (IVIG) and used at higher concentrations to suppress growth of the same Neu5Gc-expressing tumors. Hypothesizing that this polyclonal spectrum of human anti-Neu5Gc antibodies also includes potential cancer biomarkers, we then characterize them in cancer and noncancer patients’ sera, using a novel sialoglycan microarray presenting multiple Neu5Gc-glycans and control Neu5Ac-glycans. Antibodies against Neu5Gca2 6GalNAca1-O-Ser/Thr (GcSTn) were found to be more prominent in patients with carcinomas than with other diseases. This unusual epitope arises from dietary Neu5Gc incorporation into the carcinoma marker Sialyl-Tn, and is the first example of such a novel mechanism for biomarker generation. Finally, human serum or purified antibodies rich in anti-GcSTn-reactivity kill GcSTn-expressing human tumors via complementdependent cytotoxicity or antibody-dependent cellular cytotoxicity. Such xeno-autoantibodies and xenoautoantigens have potential for novel diagnostics, prognostics, and therapeutics in human carcinomas. Cancer Res; 71(9); 3352–63. 2011 AACR.
What problem does this paper attempt to address?